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Summary The present study was designed to examine the feasibility of in vivo administration of interleukin 2
(IL-2) to induce cytotoxic cell activity against tumours in human subjects. IL-2 was prepared from blood
leukocytes stimulated with phytohaemagglutinin (PHA) and partially purified by membrane chromatography
to exclude PHA. Administration of different amounts of IL-2 in vivo to 2 patients with melanoma revealed
that the initial level of IL-2 in the circulation was related to the dose given and had a half-life of -22.5
minutes. The initial and subsequent levels of IL-2 were lower than that expected to occur from equilibration
in plasma and extracellular fluid. This was not apparently due to inactivation by serum factors because fresh
human serum had little effect in vitro on the induction of mitogenic or cytotoxic activity by IL-2.
Spontaneous division of lymphocytes was increased following IL-2 administration and it is suggested that
clearance of IL-2 in vivo may reflect, in part, absorption by activated lymphocytes in the circulation. Side
effects noted shortly after administration of the partially-purified IL-2 preparations included transient pyrexia,
hypoglycaemia, increased cortisol levels, lymphocytopenia and signs of mild intravascular coagulation. No
long-term effects were noted. These initial results suggest that systemic injection of purified preparations of
II-2 may be a feasible approach to induce cytotoxic T cells in vivo.
Previous studies have shown that the lymphokine,
interleukin 2 (IL-2), appears necessary as a second
signal for the generation of cytotoxic T cells
(Lafferty et al., 1980; Wagner et al., 1980a).
Addition of IL-2 from mitogen-stimulated
lymphocytes to cultures of lymphocytes and tumour
cells was shown to induce cytotoxic activity against
syngeneic animal tumours (Mills & Paetkau, 1980;
Warren et al., 1978, 1979; Gillis & Watson, 1981)
and against autologous human malignancies such
as leukaemia (Zarling & Bach, 1979), melanoma
(Lotze et al., 1980) and various carcinomas (Vose &
Bonnard, 1982; Vose & Moore, 1981).
We have recently substantiated these studies by
showing that culture of lymphocytes from patients
with melanoma in IL-2 containing supernatants
resulted in the induction of cytotoxic cells in vitro
against autologous melanoma cells and a variety of
allogeneic target cells (Hersey et al., 1981). Culture
of the lymphocytes with tumour cells was not
necessary for the induction of cytotoxicity against
the autologous melanoma cells. Similar findings
were reported against autologous leukaemia cells
and various carcinomas (Zarling & Bach, 1979;
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Vose & Moore, 1981). IL-2 was shown previously
to act on activated T cells rather than resting T
cells (Lafferty et al., 1980) so that these results
suggested T cells activated against melanoma
antigens were present in the circulation of patients
with melanoma.
In view of these findings it seemed possible that
injection of IL-2 in vivo may lead to the induction
of cytotoxic T cells against melanoma in patients
analogous to the induction of cytotoxic T cells
against allografts in nude mice by systemic
administration of IL-2 (Wagner et al., 1980b). With
this in mind the present study was carried out to
determine whether IL-2 could be detected in vivo
after systemic injection in human subjects, and if
so, to estimate the rate of clearance of IL-2 activity
from the circulation. The results indicate that IL-2
can be detected by biological assays in the cir-
culation for -I h after intravenous injection. The
side effects noted were relatively mild and may be
further reduced by administration of more purified
preparations of IL-2.
Materials and methods
Patienits
These were 2 subjects with advanced melanoma.
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Patient I was a 26-year old male who presented
with extensive pulmonary and pleural metastases 41
years after the removal of occular melanoma. He
failed to respond to treatment with several courses
of DTIC (Dacarbazine) and progression in the size
and number of pulmonary deposits occurred in the
3 months after initial diagnosis of recurrent
melanoma. Further chemotherapy had been
refused. Tumour growth was relatively static for 2
months prior to administration of IL-2 and there
was no clinical evidence of metastases elsewhere. He
was treated as an outpatient. Seven months after
presentation bone metastases were detected on bone
scans and only palliative treatment was continued.
The second patient was a 64-year old male with
history of removal of a primary melanoma from his
right arm 31 years previously. Local recurrences
had been removed surgically 13 and 17 months
after the primary. Subsequently chemotherapy was
given for extensive local recurrences. This proved
ineffective and eventually a forequarter amputation
of his right arm was carried out 30 months after
removal of the primary. Further recurrences around
the amputation site were detected 6-10 months
after amputation and were removed surgically. At
the time of IL-2 injection subcutaneous metastases
were present on scalp, left knee and chest wall.
Multiple courses of chemotherapy had been given
over the course of his illness. Studies on the patient
were terminated when cerebral metastases were
detected. The experimental nature of IL-2
administration and the need for repeated blood
sampling after administration to obtain information
as to its effects were fully explained to both
patients and their relatives.
Production ofIL-2
IL-2 was produced from mononuclear cells
collected from relatives or friends by leukopheresis
on an Amicon celltrifuge. The yield obtained after
purification on Ficoll:Hypaque mixture (SG 1.078)
was -1010 lymphocytes. These were cultured at
5 x 106/ml in 1 litre plastic bags (Tuta Laboratories,
Lane Cove, N.S.W.) with 1% phytohaemagglutinin
(PHA) (Code HA15, Wellcome Pharmaceuticals,
Concord, N.S.W.) in RPMI 1640 (Flow
Laboratories) culture medium (without foetal calf
serum) for 24-36h. Further details of the
procedures are described elsewhere (Hersey et al.,
1981). After membrane chromatography on YM30
membranes (Amicon) in 300-ml capacity Amicon
diaflo cells to remove PHA, the volume of the
supernatant was reduced to 60-100ml by
ultrafiltration on YM5 (Amicon) membranes. This
procedure was shown previously to remove PHA
from the preparations as determined in mitogenic
assays. Each batch was filtered through Millipore
0.45 um diameter filters and sterility checked by
culture for bacteria and fungi. Assays for IL-2
activity, levels of interferon (IFN) and endotoxin
were conducted on each batch.
IL-2 assays
Assays of IL-2 in supernatants were carried out as
previously described (Hersey et al., 1981). Normal
blood lymphocytes which had been maintained in
IL-2 for 7 days after stimulation by PHA for 3
days were used as the target cell populations. The
assay cells were washed free of IL-2 and
resuspended in RPMI 1640 supplemented with 10%
foetal calf serum (FCS) (CSL batch N. 249.3). Cells
(105 in 100Ml) were placed in triplicate 70 x O0mm
round-bottomed tubes then serially diluted with the
IL-2 sample (100p1) to be assayed. Cultures were
incubated for 24h in a humidified atmosphere of
7% CO2 in air at 37°C with the addition of 2pCi
of radiolabelled iododeoxyuridine (125IUDR) (New
England Nuclear, Boston, Ma.) for the final 4h of
culture. Cells were harvested by washing 3 x in
saline and once in 5% trichloroacetic acid (TCA)
and counted in a gamma counter. 125IUDR
incorporation data were plotted against log2 of IL-
2 dilution to give a dose-response curve. The x-axis
dilution co-ordinate of the control sample which
crossed this curve at the 50% maximum 125IUDR
uptake (y-axis co-ordinate) was defined as that
value which corresponded to 1 unit of IL-2 activity.
Aliquots of the control sample of IL-2 were
repeatedly used to standardize the activity of
individual batches.
Assay of IL-2 activity in sera from the patients
was carried out as follows: The assay cells as above
were washed free of IL-2 and resuspended in RPMI
1640+10% FCS at 7.1 x 105/ml. 105 cells in 140pl
were placed in triplicate 70 x 1Omm round-
bottomed tubes followed by 60p1 of the serum
sample to be assayed. (Final serum concentration
30%). Cultures were incubated for 24h in a
humidified atmosphere of 7% CO2 in air at 37°C
with the addition of 2,pCi of radiolabelled
iododeoxyuridine 125IUDR (New England Nuclear,
Boston, Mass.) for the final 4h of culture. Cells
were harvested by washing 3 x in saline and once
in 5% trichloroacetic acid (TCA) and counts per
minute (c.p.m.) measured in a y counter.
Six control human sera were used to give a
baseline of cell turnover in the absence of IL-2 but
in the presence of 30% human serum. Units/ml
(uml-1) of IL-2 activity in serum were measured
from a standard curve prepared by addition of 40pl
of different dilutions of the infused IL-2 in RPMI
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before administration of IL-2. Aliquots (100p1) of
these dilutions were then added to 100 p1 of cells in
RPMI as described above for assay of IL-2 in
serum samples. (Final concentration of serum,
30%). A plot of uml-1 for these samples against
125IUDR incorporation enabled the construction of
a standard curve from which the uml'- in the
patient's serum samples after infusion of IL-2 could
be calculated by reading from the graph against the
appropriate 125IUDR incorporation value.
Endotoxin assays
The supernatant was assayed for endotoxin content
by the Limulus Amebocyte Lysate (LAL) assay
(Sigma E Toxate Kit). One hundred-pl of the
supernatant and 10-fold dilutions of the
supernatant were mixed with 100 p1 of the LAL and
incubated for h. This was compared with the
coagulation seen in 10-fold dilutions of the 2 pgml
standard endotoxin supplied in the kit.
Electrophoresis in polyacrylamide gels in sodium
dodecylsulphate (PAGE-SDS)
Samples of IL-2 were analysed by PAGE-SDS
using a Pharmacia PAA 4/30 gradient gel
(Pharmacia, Uppsala, Sweden). The electrophoresis
buffer used was 0.04M Tris; 0.02M sodium acetate;
pH 7.4 with 2mEDTA and 0.2% SDS. Samples
were heated at 90°C for 5min and diluted 1: 1
before electrophoresis with a solution of 20mM
Tris-HCI pH 8.0, 2mEDTA 5.0% SDS, 10%
metcaptoethanol, 15% sucrose and 0.01%
bromphenol blue. Pre-electrophoresis (without
samples) was for h at 70V. Twenty-pl of the
diluted samples were applied and electrophoresed
for 3-5h at 100V.
Interferon assays
IFN assays were based on the cytopathic effect of
Encephalomyocarditis (EMC) virus on Vero cells.
The endpoint was taken as the amount of
interferon (in units/ml) to give 50% protection of
the cell layer. Full details of the assay are described
elsewhere (Hersey et al., 1982). IFN titres were
determined relative to a leukocyte international
standard (G-023-901-527 from the Antiviral
Substances Programme of the National Institute of
Allergy and Infectious Diseases, NIH Bethesda,
Maryland 20014, U.S.A.) or relative to a laboratory
standard previously related to an international
standard.
Cytotoxic assays
The 5"Cr release assays and target cells used in
studies on the effect of fresh serum on IL-2 induced
cytotoxic activity are fully described elsewhere
(Hersey et al., 1981).
Results
Effect of PHA and IL-2 on unstimulated blood
mononuclear cells and IL-2 dependent cells
As shown in Table I, 1% PHA had little
stimulating activity on the IL-2 dependent cells
used in the assay. The table also shows that
attempts to remove PHA from the crude IL-2
preparations by filtration through YM30
membranes and then concentration on YM5
membranes was effective in removing mitogenic
activity for normal unstimulated blood
lymphocytes.
IL-2 assays
Assay of the IL-2 activity in the partially purified
supernatants given to the patients is shown in
Figure 1. An IL-2 preparation prepared from
spleen cells from a patient with melanoma
Table I Effect of PHA and IL-2 preparations (before and after membrane chromatography) on unstimulated
lymphocytes and IL-2 dependent lymphocytes
Unstimulated blood lymphocytes* IL-2 dependent lymnphocytes
3-day incubation (mean c.p.m. + s.d.) 2-day incubation (mean c.p.m. + s.d.)
Final dilution in assay 32 8
PHA 1% 48,798+ 596 19,488 +3155 2197+1022 2,958+ 346 1,726+ 123 1,376+ 536
IL-2 prefiltration 46,822+3610 11,125+2050 2600+ 900 144,938+3747 103,589+ 1056 29,085+1076
IL-2 postfiltration 2,792+ 303 1,495 + 251 1403+1246 92,978 + 110 39,596+2716 4,658+ 453
*From normal volunteers.126 '. BINDON et al.
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Figure 1 Assay of IL-2 activity in partially purified
supernatants from PHA stimulated human
mononuclear cells. Relative to the standard, (0-0) at
100 uml- theIL-2giventoPatient Ihad 100 uml-' 0-
0 and 81 uml-P 0-0. The IL-2given to Patient 2 had
132uml-' C-r-C and 566uml-' *-. Values
indicated are mean +I s.d.
containing .100 uml-l was used as a standard during
the studies. Patient 1 (48kg) received 14,000 and
5,000 units and Patient 2 (75kg) 17,000 and 67,000
units.
Influence ofhuman serum on mitogenic and cytotoxic
activity induced by IL-2 in vitro
Increasing quantities of non-heat inactivated fresh
serum from a normal subject were added to a
constant amount (3 uml- 1) of the standard IL-2
preparation. As shown in Table II the serum had
no significant effect on IL-2-induced 125IUDR
incorporation in a standard IL-2 assay until the
final concentration of serum in the assay exceeded
25%. At a final serum concentration of 75% the
percentage inhibition was still only 50%.
The effect of fresh unheated serum on the
induction of cytotoxic activity in lymphocytes from
2 patients with melanoma by IL-2 was also
examined. As shown in Table III, the cytotoxic
activity after incubation for 6 days in medium
containing IL-2 (2uml-1) plus 10% FCS or fresh
human serum was comparable against the
autologous tumour cells. Cytotoxicity of
lymphocytes cultured in IL-2 plus fresh human
serum against the allogeneic melanoma and non-
melanoma cells was either similar or showed a
reduction of 17-28% when compared to that of
lymphocytes cultured with IL-2 and FCS. In these
experiments lymphocytes cultured in RPMI+FCS
alone were not viable after 6 days of culture.
PAGE-SDS analysis of the IL-2 containing
supernatants prepared by membrane
chromatography as described revealed fractions
with molecular weights (mol. wts.) of -10, 13-16,
18, 20, 22, 24, 28, 32 and 67 Kilodaltons (Kd). The
predominant fraction was that detected at 13-16Kd
which from previous studies was likely to contain
IL-2 (Mier & Gallo, 1980). The 28Kd fraction may
have been a contaminant of PHA in that when the
same amount of PHA as used for IL-2 production
was processed as for IL-2 production and analysed
by PAGE-SDS, a 28Kd fraction was detected.
(Before membrane chromatography the major
fraction in the PHA had a mol. wt. of -32Kd.
Minor fractions were detected with mol. wts. of
28 and 12Kd). The 67Kd fraction in the IL-2
preparations may have been human serum albumin
non-specifically absorbed to the human
lymphocytes used for IL-2 preparation. (FCS was
not added to the leukocytes during preparation of
IL-2).
Endotoxin and interferon content of the partially
purified supernatants
The limit of detection of the endotoxin standard
with the LAL was 0.2ng. By comparison with the
standard endotoxin preparation in the kit, the IL-2
preparations had <2ng/ml of endotoxin.
The IFN levels were <2.5uml-' in the injected
preparations.
Clearance ofIL-2from the circulation
After i.v. injection of IL-2, blood samples were
taken at regular intervals. Serum from these
samples were assayed for IL-2 activity as described.
The results in Figures 2 and 3 indicate an
exponential clearance of IL-2 from the circulation
over 1 h. A plot ofthe logarithm ofthe counts against
time revealed that clearance of half the IL-2 activity
from the circulation (Ti) took 22.5min on both
occasions in Patient 1. The equivalent Ti times in
Patient 2 were 20 and 25min respectively. A dose-
response curve for the infused IL-2 in a 30%
dilution of the patient's pre-treatment serum was
constructed as described to determine the units of
IL-2 activity in the serum of the 2 recipients. The
initial uml-1 obtained in the serum related to the
dose given in that particular patient e.g. as shown
in Figure 2, in Patient 1 injection of 14,000 units
gave an initial level of 3 uml-1 whereas 5,000 units
gave an initial level of luml-'. In Patient 2 the
injection of 17,000 and 67,000 units gave initial
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Table 1I Effect of serum concentration on lymphocyte stimulation (125IUDR incorporation) by IL-2
% Serum 75 50 25 12.5 6.25 0
c.p.m. with 3u/ml IL-2
+s.d. 17,559+1864 18,522+1129 26,176+1888 27,232+2217 26,105+823 28,504+251
c.p.m. in absence of IL-
2
+s.d. 4,985+ 344 5,367+ 440 7,043+ 309 7,568+ 375 6,595+430 6,755+388
% Inhibition of
IUDR uptake
caused by
presence of seruin 50.3 45.9 10.7 5.8 11.0 0
Mean values + s.d. for 125IUDR uptake by 105 cells.
Table III Effect of presence of 10% autologous serum on generation of cytotoxic T cells and 125IUDR
incorporation in 6-day cultures
Cell-mediated cytotoxicity 125IUDR incorporation
(% "mCr release above baseline) c.p.m.
Autol. MM200 MM96 Chang K562 MCF-7
PATIENT I
Day 0 7+2 9+0.5 4+1.5 26+1 3+1 1,928+ 159
+Dy0%FCS 36+1 70+1 65+2 64 35+1 16,098+1215
Day 6 36+1 58+0.5 64+2 59 29+4 21,737+4163
± 10% aut. serum (17) (17)
PATIENT 2
Day 0 n.t. 8+1.5 10 2 15 4+1 1,917± 107
+y0%FCS 31 34 48+3 60+0.5 60+2 29+3 8,801+ 768
Day 6 26 28+2 38+3 43+3 62+1 23±1 16,719+1817
+ 10% aut. serum (18) (21) (28) (21)
Mean values +s.d. Effector:target cell ratios 100:1 except for K562 = 30:1. MM200 and MM96 =melanoma
cell lines; MCF-7=breast carcinoma line. K562=myeloid cell line. Chang=liver cell line. Figures in parentheses
indicate percentage inhibition ofcytotoxicity in presence ofautologous serum.128 C. BINDON et al.
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Figure 2 Clearance of IL-activity from the circulation of Patient 1 after i.v. injection of 14.000 units and 27
days later 5,000 units. The dashed line indicates the mean '25IUDRc.p.m. of IL-2 dependent lymphocytes
in the serum of 6 individual normal subjects (mean+s.d., 3915+550c.p.m.). The "IUDRc.p.m.
corresponding to 0.25 to 3u/ml of the standard IL-2 assayed in 30% serum of the patient is shown on the
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Figure 3 Clearance of IL-2 activity from the circulation of Patient 2 after i.v. injection of 17,000 units and
67,000 units 27 days after the first injection. The dashed line indicates the mean IL-2 activity in 6 sera from
normal subjects (mean+s.d., 4056+305c.p.m.) T1 for clearance of IL-2 was 20 min and 25 min respectively.
levels of
- 1.25 and 6 units respectively (Figure 3).
The levels of IL-2 obtained with a given dose of
IL-2 varied between the 2 patients e.g. in Patient 1
a dose of 14,000 u gave - 3 u ml- 1 in the circulation
whereas a dose of 17,000 u in Patient 2 gave
1 uml-'. The body weight of Patient 1 was 48kg
and that of Patient 2, 75kg. (Estimated plasma
volume for Patient 1 was 1.921. For Patient 2,
2.921. Estimated total extracellular fluid for Patient
1 was 9.121 for Patient 2, 13.871). The difference in
IL-2 activity obtained in the serum between the 2
patients for a given dose was therefore not merely
due to the difference in body weight. This aspect is
discussed further below.
125IUDR incorporation into blood mononuclear cells
after IL-2 injection
As shown in Figure 4, in both patients the
incorporation of 125IUDR into blood
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Figure 4 1251IUDR uptake by blood mononuclear cells after i.v. injection of 14,000 and 5,000 units of IL-2
in patients 1(A) and 17,000 and 67,000 units in Patient 2(B). Points indicated are means+s.d. of triplicate
samples of 105 mononuclear cells. Uptake was measured over a 4-h culture period in vitro in the presence of
2pCi of 1251UDR.
mononuclears was increased in blood samples taken
immediately after IL-2 injection and returned to
baseline levels by 24h. In Patient 1 there was no
significant increase in 125IUDR uptake in samples
taken from Day 1 after the first or second injection
of IL-2. This also applied to Patient 2 after the first
injection but there was a significant increase in
135IUDR incorporation in leukocytes taken 6, 7, 9
and 13 days after the second IL-2 injection.
Haematological changes after i.v. injection of the
partially purified IL-2 containing supernatants
The haematological data obtained from sequential
studies of the 2 patients after IL-2 administration is
recorded in Table IV. The results can be
summarized as follows: (1) No significant changes
occurred in haemoglobin (Hb) levels in Patient 1
(who had metastases in bone marrow). In Patient 2
there was a slight increase in Hb at Days 7-12 after
both injections. This increase coincided with an
increase in platelet counts, and myelocytes and
metamyelocytes. (2) The total white blood cell
(WBC) count and the neutrophil (neut) count
showed a marked increase 2-4h after the injections
but returned to normal by Day 1 (1 d) or Day 2
(2d). (3) Lymphocyte (lym) counts were reduced
immediately after the injections. They returned to
pre-treatment values 1 day after the injections in
Patient 1. In Patient 2 the lymphocyte count tended
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Table IV Haematological changes after injection ofsupernatants containing IL-2
Time after injection of IL-2
Patient 1 14,000 5,000
units units
0 4h Id 2d 3d 7d 13d 25d 0 4h Id 6d 8d 12d 15d
Hb.1 11.9 13.0 11.6 11.4 11.5 11.2 11.0 11.0 11.0 10.6 10.6 10.6 10.1 10.7
WBC2 7.1 14.7 7.6 5.6 6.8 6.1 5.2 5.7 5.6 15.4 8.4 7.8 5.2 6.3 5.0
Neut. 5.6 13.24 6.0 3.9 5.8 4.9 4.2 4.0 4.2 14.3 7.2 5.8 4.0 5.2 4.0
Lymph. 0.7 0.43 0.98 1.1 0.5 0.48 0.57 1.2 0.7 0.46 0.9 1.3 0.7 0.6 0.6
Mono. 0.8 1.0 0.45 0.4 0.47 0.6 0.3 0.3 0.6 0.6 0.2 0.6 0.5 0.4 0.4
Platelets 326 289 347 317 332 412 439 341 360 345 381 404 445 451 339
Patient 2 17,000 67,000
units units
0 4h Id 2d 7d 9d 12d 0 4h Id 2d 3d 7d 8d 9d 12d 16d 21d 23d
Hb. 12.9 13.3 12.2 12.8 13.2 13.8 13.6 13.4 12.3 12.6 11.9 12.6 13.5 14.2 14.0 13.3 13.5 13.0 13.0
WBC 9.6 20.9 11.6 8.1 9.4 9.3 8.5 12.2 23.5 32.6 11.9 8.7 10.1 10.4 12.6 10.6 11.5 8.0 8.4
Neut. 7.1 19.6 10.3 7.0 7.5 7.9 7.44 9.5 22.8 30.0 10.5 7.5 7.34 8.84 10.84 9.1 10.5 6.1 6.9
Lymph. 2.1 0.63 1.04 0.81 1.4 1.3 0.77 1.59 0.5 1.3 0.83 1.2 2.2 0.9 1.1 0.8 0.7 1.5 1.2
Mono. 0.3 0.4 0.3 0.3 0.5 - 0.3 0.8 0.2 0.9 0.6 0.1 0.4 0.6 0.5 0.6 0.3 0.3 0.3
MM&Myl. - - occ. 1 occ. .--
Platelets 328 295 312 324 404 472 471 443 383 377 337 371 430 518 508 483 477 369 373
1g/dl.
2Leukocyte and platelet counts x 10-91-1.
3Occasional atypical lymphocytes noted.
4Occasional hypersegmented neutrophils.
to remain below the initial pre-treatment values. In
Patient 1 there was a secondary reduction of
lymphocyte numbers after the first injection on
Days 3, 7 and 13. In Patient 2 there also appeared
to be secondary reduction in lymphocyte count on
Day 2 following both injections and Days 12 and
16 after the second injection. (4) Monocyte (mono)
counts showed no significant changes. (5) Platelet
counts showed a reduction of 5-14% of pre-
treatment counts by 4h after the injections. This
appeared related to the dose of IL-2 injected and
persisted for 1-2 days.
Clinical observations
The following changes were observed clinically after
i.v. injection of the IL-2 containing supernatants.
Rigors developed 10-15min following injection
and lasted for f-I h. This was followed by pyrexia
at 38-39°C lasting from 2-6h. The duration of the
pyrexia was related to the number of IL-2 units
injected. After 5,000 units the pyrexia lasted for
2 h and after 67,000 units for 6h. Tachycardia of
100-120 was noted during the pyrexia and a
transient drop of blood pressure of 5-15 mmHg
diastolic occurred at the beginning of the pyrexia.
The first patient developed nausea and vomiting
15min after the second injection of 5,000 units. The
second patient developed transient nausea 10-
15min after the second injection of 67,000 units.
Patient 1 was ambulant and attended for treatment
as an outpatient. Patient 2 was an inpatient for
stabilization of anti-coagulant therapy (given for a
deep calf vein thrombosis which developed after his
last surgical treatment) and for treatment of an
ulcer over the lateral aspect of his left ankle. No
clinically apparent adverse effects were noted in the
days subsequent to the injections.
Immunoglobulin levels No significant change in
immunoglobulins A, G or M levels were detected in
serum samples from the 2 patients taken at weekly
intervals over the study period (8-10 weeks).
Auto-antibodies Auto-antibodies to red blood
cells, anti-nuclear factors, parietal cells, smooth
muscle cells, thyroid tissue and mitochondria were
not detected in pre-treatment serum samples or inSYSTEMIC ADMINISTRATION OF IL-2 131
samples taken 3 weeks after each treatment.
Rheumatoid factor was detected by the latex
agglutination test both before and after treatment
in Patient 2.
Cortisol levels An increase in cortisol levels were
observed within 2h of the injections. The degree of
the rise appeared related to the dose of IL-2 given.
In Patient 2 after injection of 17,000 units peak
cortisol levels of 720nM/l were seen at 4h. After
67,000 units peak levels of 1780nM/l were seen at
4h. Pre-injection values were 280 and 270nM/l
respectively. The levels had returned to within the
normal range 20h after the injections (270 and
415nM/l respectively. Normal range 280-830nM/l).
Liver enzymes and blood glucose levels No
significant change in the enzyme alkaline
phosphatase, lactic dehydrogenase, glutamyl
pyruvate, glutamyl oxalacetic and y-glutamyl
transaminases were recorded at 1, 4 and 24h after
the IL-2 injection. The serum glucose level in
Patient 1 before and at 1, 4 and 24h after injection
of 14,000 units was 4.4, 3.3, 6.5 and 5.1 mMl-'
respectively. (Normal venous fasting levels 3.9-
6.1mMl-1). In Patient 2 levels of blood glucose
before and at 1, 4 and 24h after injection of 67,000
units was 5.3, 3.3, 5.3 and 5.8 respectively.
Effect of IL-2 on the coagulation system Patient 2
was on anti-coagulants and was not studied. At
45min after injection of 14,000 units in Patient 1
there was significant prolongation of the thrombin
time from 14 to 30sec and of the partial
thromboplastin time with kaolin (PTTK) of 27 to
35 sec. These had returned to normal by 4h.
Moderate levels of fibrinogen degradation products
(FDPs) were detected at 45min (40-80ngml-1) and
fibrinogen levels were also low 45min after the
injections (15mgml-') (Normal range, 200-
400mg/ml). The latter had returned to normal by
4h but 10-40ngml of FDPs were still present at
this time.
IFN levels in serum following administration ofIL-2
containing supernatants No significant levels of
IFN (<1 unit/ml) were detected in serum samples
taken at 1 and 4h or at the daily intervals shown in
Figures 2 and 3 after injection of 14,000 units in
Patient 1 and 67,000 units in Patient 2.
Complement levels No significant changes
occurred in the C3 or C4 levels after the injections
in either patient.
Discussion
The dose of IL-2 given to the subjects in this study
was selected so that an initial level of at least 2u/ml
in plasma would be obtained as this was the level
used in vitro for induction of cytotoxic T cell
activity (Hersey et al., 1981). Based on an expected
plasma volume of - 4% of body weight and
assuming no destruction or absorption of the IL-2
it would be expected that 14,000u in Patient 1
would give an initial value of 7.3 uml' (calculated
plasma volume 1.921) and 17,000u in Patient 2 an
initial value of 5.8uml- 1 (calculated plasma volume
2.921). Observed values were approximately 3u/ml
and 1 u/ml respectively. Similarly on the assumption
that IL-2 equilibrated in total extracellular fluid
(TEF) and that this was 19% of body weight it
would be expected that the final level in Patient 1
would be 1.5u.ml-1 (calculated TEF=9.121) and
1.22u.ml in Patient 2 (calculated TEF=13.871). In
fact zero levels were seen at 1 h. [Equivalent values
for the second injection in both patients were
Patient 1, expected initial 2.6uml' (observed
approximately 1.25u/ml, Patient 2 expected initial
23 u/ml- 1, observed approximately 6uml-')].
The discrepancy between the expected and
observed IL-2 values in the circulation may be the
result of several factors. One possibility is the IL-2
may be inactivated by factors in serum as reported
to occur in mice (Wagner et al., 1980a). Similar
inactivation of IL-2 by human serum was not
detected in the present studies. The mitogenic
activity of IL-2 on activated T cells in vitro was
only inhibited by high concentrations of fresh
human serum and the induction of cytotoxic cells in
vitro by IL-2 in autologous serum was comparable
or only moderately reduced compared to that in
FCS. We cannot exclude that factors inhibiting
mitogenesis may have been released into the serum
in vivo following IL-2 administration and that these
may have influenced the clearance rates by their
effect on the bioassay used in the study.
A second explanation for loss of IL-2 activity is
that it was absorbed by activated T cells in vivo as
shown to occur in vitro. (Smith et al., 1979; Watson
& Mochizuki, 1980). At high cell concentrations in
vitro 70% of IL-2 activity was found to be
absorbed in 30min (Smith et al., 1979) which is
comparable to the clearance rate from the patient's
serum found in the present study. Absorption of
IL-2 by activated lymphocytes may explain why
different levels of IL-2 were seen in the 2 patients
for a given dose of IL-2. Patient 1 had a lower
lymphocyte count than Patient 2 and hence less
absorption of IL-2 and relatively higher serum
levels of IL-2 may have occurred.
The latter explanation was supported by evidence132 C. BINDON et al.
of increased division of cells in the circulation after
injection of the IL-2 containing preparations. This
was consistent with absorption to and activation of
cells in the circulation which expressed IL-2
receptors. Recent studies suggest the latter cells are
activated into the G1 phase of the cell cycle by
interaction with antigen but require IL-2 for
subsequent cell division (Kristensen et al., 1982).
A number of clinical and biochemical effects
were observed in the recipients of the IL-2
containing preparations which may have reflected
the activity of contaminating monokines and
lymphokines in the preparation, e.g. pyrexia may
have resulted from interleukin I (IL-1) in the
supernatants as the latter is believed to be
synonymous with endogenous pyrogen (Murphy et
al., 1980). Similarly the transient hypoglycaemia
and increase in FDPs may indicate the activity of
such factors as glucocorticoid antagonizing factor
(Moore et al., 1978) and thromboplastins (Geczy &
Hopper, 1981) released from monocytes in the
blood leukocyte preparations during IL-2
production. The increased platelet count,
haemoglobin and metamyelocytes noted at 7 days
may indicate the presence of colony stimulating
factors in the preparations.
Elevation of glucocorticoids in the circulation
was previously noted after injection of lymphokine
preparations in rodents (Besedovsky et al., 1981)
and may have been responsible in part for the
neutrophilia and lymphocytopenia noted hours
after the injections. Both the latter are well known
systemic effects of corticosteroids. The systemic
effects noted in these studies were similar to those
reported after administration of a lymphokine
preparation (Dumonde et al., 1982) and
recombinant IFN except that neutropenia rather
than neutrophilia was noted after the latter
(Gutterman et al., 1982). IFN was not detected in
the IL-2 containing supernatants in the present
study and it seems likely that the side effects
common to these procedures are in part due to a
stress response.
These results highlight the need for
administration of purified preparations of IL-2 to
allow the effects of IL-2 in vivo to be clearly
defined. The present study, however, provides some
encouragement that systemic administration of IL-2
may be a feasible approach for the activation of T
cells in vivo. Such an approach would be technically
much simpler than injection of cytotoxic T cells
grown in vitro in the presence of IL-2 as described
by previous authors (Mills et al., 1980; Warren et
al., 1979; Gillis & Watson, 1981) and may allow
activation of lymphocytes at the site of tumour
growth. Although the half-life of 20-25min for IL-
2 in the circulation appears relatively short this
does not appear to be due to inactivation by serum
factors. If subsequent studies confirm that clearance
is at least in part due to absorption to activated T
cells this may be sufficient to trigger these cells into
cytotoxic activity despite the subsequent absence of
detectable IL-2 in the circulation. Further studies
with purified IL-2 preparations are required to
answer these questions.
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